【#ARTICLES|#Biomed】 BioXcel Therapeutics Announces FDA Approval of #IGALMI™

對於精神分裂相關疾病困擾提供助益 “There are large numbers of patients who experience agitation associated with schizophrenia and bipolar disorders, and this condition has been a long-standing challenge for healthcare professionals to treat”

多了另一種治療的選擇 “The approval of #IGALMI, a self-administered film with a desirable onset of action, represents a milestone moment. It provides healthcare teams with an innovative tool to help control agitation. As clinicians, we welcome this much-needed new oral treatment option.”



 

Source |https://l.facebook.com/l.php?u=https%3A%2F%2Fwww.globenewswire.com%2Fnews-release%2F2022%2F04%2F06%2F2417422%2F0%2Fen%2FBioXcel-Therapeutics-Announces-FDA-Approval-of-IGALMI-dexmedetomidine-Sublingual-Film-for-Acute-Treatment-of-Agitation-Associated-with-Schizophrenia-or-Bipolar-I-or-II-Disorder-in-.html%3Ffbclid%3DIwAR2Ss--kVuXkrilmbm00_dZVkFmOkSpty9q6oAjFzIE84HOXG655WQuJH2g&h=AT3b6GN614LpA042boZYQXBBddACZx4jVXhbdvG1RZbli_h6e1KxUC5nEyQ2ly3A77FGBy5t8Vu9z6xkrW0Gw4WSXo4F7SHi5qs_27A7aOE2ezbbHOMphyKpQ98dmDceMvvv&__tn__=-UK-R&c[0]=AT26uptfzRJxyQQhkNGkrgiGUgAnW_eyCif2iDs_uHKCGOIiAQn64t9Jj055maubeT0g1FWRFAmmqwkn-l_EPjMdBa-BW1DH8Nqj15rT7z_BwQa7f5SQe2-a2JRYmE5DXOLrORW79hVdTCR2M39S6utWZeflPIPlfR9oxYru0rCSA-erNOsbXSw6byt_0oHsrFbi8Q

0 views0 comments